{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-045465","form_type":"8-K","ticker":"WHWK","cik":"0001422142","company_name":"Whitehawk Therapeutics, Inc.","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.410393+00:00","generated_at":"2026-05-30T04:27:07.037850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aadi Bioscience Q3 2024 FYARRO sales $7.2M (+21% YoY); net loss $12.5M","bullets":["FYARRO net product sales of $7.2M in Q3 2024, up 17% from Q2 2024 and 21% from prior year.","Net loss of $12.5M for Q3 2024 vs $16.3M for Q3 2023; operating expenses $20.6M incl $2.6M restructuring.","Cash, equivalents, and short-term investments $62.6M as of Sep 30, 2024; expected to fund ops into 2H 2026.","Completed wind-down of PRECISION1 trial; Phase 2 trials for EEC and NETs enrolled 24 and 12 patients.","Comprehensive strategic review ongoing to maximize shareholder value; no timeline provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-045465","json":"https://secwatch.observer/filing/0001628280-24-045465.json","markdown":"https://secwatch.observer/filing/0001628280-24-045465.md","text":"https://secwatch.observer/filing/0001628280-24-045465.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024045465/0001628280-24-045465-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422142/000162828024045465/aadi-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:27:07.037850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}